Eloxatin
Childhood Central Nervous System Mixed Germ Cell Tumor
National Cancer Institute (NCI)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Childhood Central Nervous System Mixed Germ Cell Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vorinostat National Cancer Institute (NCI) | Phase 1 | CCC |
gw786034 National Cancer Institute (NCI) | Phase 1 | CC |
Bortezomib National Cancer Institute (NCI) | Phase 1 | CC |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 1 | CC |
FLUOROURACILUM National Cancer Institute (NCI) | Phase 1 | CC |
rg4733 National Cancer Institute (NCI) | Phase 1 | C |
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →